Novo Integrated Sciences Begins Disbursement Process for SBLC Leasing and Monetizing Program.
Novo Integrated Sciences, Inc. (NASDAQ: NVOS) recently announced that it has received notice of the commencement of disbursement for the complete monetization of a Standby Letter of Credit ("SBLC"). $Novo Integrated Sciences(NVOS.US$
https://stockregion.app/p/health-and-wellness-company-receives
Novo Integrated Sciences, Inc. (NASDAQ: NVOS) recently announced that it has received notice of the commencement of disbursement for the complete monetization of a Standby Letter of Credit ("SBLC"). $Novo Integrated Sciences(NVOS.US$
https://stockregion.app/p/health-and-wellness-company-receives
Silo Pharma and Resyca BV Enter Device and CMC Development Master Plan.
Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company, announced that it has entered into a Device and CMC Development Master Plan with Resyca BV, a medical technology provider. This collaboration is particularly focused on the advancement of Silo's lead candidate, SPC-15, an intranasal prophylactic treatment for post-...
Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company, announced that it has entered into a Device and CMC Development Master Plan with Resyca BV, a medical technology provider. This collaboration is particularly focused on the advancement of Silo's lead candidate, SPC-15, an intranasal prophylactic treatment for post-...
1
BriaCell Quadruples Progression-Free Survival in Metastatic Breast Cancer Patient.
The field of oncology has witnessed numerous advancements over the years, yet metastatic breast cancer continues to pose challenges. However, recent developments reported by BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) offer a glimmer of hope. The clinical-stage biotechnology company, known for its innovative immunot...
The field of oncology has witnessed numerous advancements over the years, yet metastatic breast cancer continues to pose challenges. However, recent developments reported by BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) offer a glimmer of hope. The clinical-stage biotechnology company, known for its innovative immunot...
Haystack Oncology and Lisata Therapeutics Collaborate on Evaluating Pancreatic Cancer Therapy Efficacy Using MRD Technology.
Haystack Oncology announced a research collaboration with Lisata Therapeutics Inc. This partnership aims to leverage Haystack's cutting-edge minimal residual disease (MRD) technology to assess the efficacy of innovative treatments for metastatic pancreatic cancer. $Lisata Therapeutics(LSTA.US$
https://stockregion.app/p/therapeutics-company-announces-collaboration
Haystack Oncology announced a research collaboration with Lisata Therapeutics Inc. This partnership aims to leverage Haystack's cutting-edge minimal residual disease (MRD) technology to assess the efficacy of innovative treatments for metastatic pancreatic cancer. $Lisata Therapeutics(LSTA.US$
https://stockregion.app/p/therapeutics-company-announces-collaboration
Siyata Mobile Announces New Orders for U.S. Wireless Carriers Valued at More Than $4.5 Million.
On July 18, 2024, Siyata Mobile Inc., listed on Nasdaq under the ticker SYTA, announced that it has received orders valued at over $4.5 million for its SD7 handsets and accessories from U.S. wireless carriers. $Siyata Mobile(SYTA.US$
https://stockregion.app/p/mobile-company-secures-45-million
On July 18, 2024, Siyata Mobile Inc., listed on Nasdaq under the ticker SYTA, announced that it has received orders valued at over $4.5 million for its SD7 handsets and accessories from U.S. wireless carriers. $Siyata Mobile(SYTA.US$
https://stockregion.app/p/mobile-company-secures-45-million
1
Lexaria Bioscience Corp. Reports Positive Interim Body Weight Results from Diabetes Animal Study.
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW), a global innovator in drug delivery platforms, recently announced interim results from the first four weeks of dosing in its ongoing diabetes animal study, WEIGHT-A24-1 (the "Study"). $Lexaria Bioscience(LEXX.US$
https://stockregion.app/p/bioscience-company-reports-positive-6c7
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW), a global innovator in drug delivery platforms, recently announced interim results from the first four weeks of dosing in its ongoing diabetes animal study, WEIGHT-A24-1 (the "Study"). $Lexaria Bioscience(LEXX.US$
https://stockregion.app/p/bioscience-company-reports-positive-6c7
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets.
CytoMed Therapeutics Limited (NASDAQ: GDTC), a Singapore-based biopharmaceutical company, has recently made a acquisition aimed at bolstering its position in the allogeneic, off-the-shelf donor-derived gamma delta (γδ) T cells technology sector. Through its wholly-owned subsidiary, IPSC Depository Sdn Bhd, CytoMed has acquired the licence and certain assets of C...
CytoMed Therapeutics Limited (NASDAQ: GDTC), a Singapore-based biopharmaceutical company, has recently made a acquisition aimed at bolstering its position in the allogeneic, off-the-shelf donor-derived gamma delta (γδ) T cells technology sector. Through its wholly-owned subsidiary, IPSC Depository Sdn Bhd, CytoMed has acquired the licence and certain assets of C...
1
Guardforce AI Expands Retail Footprint Across Asia Pacific.
Guardforce AI Co., Limited (“Guardforce AI” or “the Company”) (NASDAQ: GFAI, GFAIW), a provider of integrated security solutions, AI, and Robot-as-a-Service (RaaS), continues to make strides in the retail sector. The company's wholly owned subsidiary in Mainland China, Beijing Wanjia Security System Limited ("Beijing Wanjia"), has recently expanded its contracts wi...
Guardforce AI Co., Limited (“Guardforce AI” or “the Company”) (NASDAQ: GFAI, GFAIW), a provider of integrated security solutions, AI, and Robot-as-a-Service (RaaS), continues to make strides in the retail sector. The company's wholly owned subsidiary in Mainland China, Beijing Wanjia Security System Limited ("Beijing Wanjia"), has recently expanded its contracts wi...
Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing.
On July 12th, Aditxt, Inc. (NASDAQ: ADTX), alongside its wholly owned subsidiary Adifem, Inc., and Evofem Biosciences, Inc. (OTCQB: EVFM), announced an amendment and restatement of their Merger Agreement. This revised agreement addresses several key pre-closing issues deemed essential for Evofem’s future success, including interim financing needs. Among the not...
On July 12th, Aditxt, Inc. (NASDAQ: ADTX), alongside its wholly owned subsidiary Adifem, Inc., and Evofem Biosciences, Inc. (OTCQB: EVFM), announced an amendment and restatement of their Merger Agreement. This revised agreement addresses several key pre-closing issues deemed essential for Evofem’s future success, including interim financing needs. Among the not...
1
Shimmick Awarded $27.6 Million Subcontract for Sunol Valley Water Treatment Plant Ozonation Project.
Shimmick (NASDAQ: SHIM), a leading water infrastructure company, has announced a achievement in its portfolio. The company has secured a subcontract worth $27,583,595 for electrical work on the Sunol Valley Water Treatment Plant Ozonation Project. This subcontract is part of a larger prime co...
Shimmick (NASDAQ: SHIM), a leading water infrastructure company, has announced a achievement in its portfolio. The company has secured a subcontract worth $27,583,595 for electrical work on the Sunol Valley Water Treatment Plant Ozonation Project. This subcontract is part of a larger prime co...
1